Chronic hand eczema

Diepgen, T. L.

doi:10.1007/s00105-008-1560-9

Cited by 11 publications

(6 citation statements)

References 57 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With new therapeutic options (5) and several new national guidelines on the management of hand eczema (4, 7-10) the disease became more and more a centre of interest in dermatology. In addition, CHE is the most common occupational disease and therefore of high socioeconomic impact (11,12). Health-related costs and quality of life in CHE have also been investigated in several studies during the past years (13)(14)(15)(16).…”

mentioning

confidence: 99%

Chronic Hand Eczema: Perception and Knowledge in Non-affected Individuals from General and Dermatological Practice

Letulé¹,

Herzinger²,

Schirner³

et al. 2014

Acta Derm Venerol

View full text Add to dashboard Cite

Misunderstanding and stigmatisation are common problems encountered by patients with hand eczema. Various misconceptions about the disease circulate in the general population. Although hand eczema has gained more attention in dermatology during the past years, information on public perception of the disease is still lacking. The aim of our study was to investigate perception of and level of knowledge on the subject hand eczema. There were 624 patients included from 2 general medicine practices and 2 dermatological practices. A self-administered questionnaire was filled out by the participants, covering issues on history of hand eczema, level of knowledge and attitude towards a clinical photograph of hand eczema. We found that a larger proportion of individuals from dermatological practice were more familiar with hand eczema as a disease than those from general medical practice. Women knew significantly more about and had a more positive perception of the disease than men. Our results imply that the level of knowledge on hand eczema in the general public is rather low and influenced by prejudice.

show abstract

mentioning

confidence: 99%

Chronic Hand Eczema: Perception and Knowledge in Non-affected Individuals from General and Dermatological Practice

Letulé¹,

Herzinger²,

Schirner³

et al. 2014

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“… 10 Hand eczema can have a great influence on patients' life and quality of life because of the physical, psychological and social consequences. 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

Psoralen plus ultraviolet A (PUVA) soaks and UVB TL01 treatment for chronic hand dermatoses

2012

View full text Add to dashboard Cite

Chronic eczematous hand dermatoses with and without contact allergies are complex diseases, which makes it a challenge to select the best treatment and obtain an optimal patient experience and a satisfactory treatment result. The aim of this study was to evaluate retrospectively the clinical effect and patient experience of local treatment with psoralen plus ultraviolet A (PUVA) soaks and TL01 phototherapy for severe chronic hand dermatoses, and also to evaluate the quality of life for the subgroup of patients with allergic contact dermatitis including Compositae allergy. A retrospective evaluation of results for 94 consecutive patients having received a total of 121 treatment courses with local PUVA soaks or TL01 phototherapy for one of the following diagnoses (n=number of treatment courses): psoriasis (n=19), hyperk-eratotic hand eczema (n=27), Pustulosis Palmoplantaris (PPP) (n=22), vesicular eczema (n=16), Compositae dermatitis (n=24), and allergic contact dermatitis (n=13). Moreover, semi-structured interviews with 6 selected patients having multiple contact allergies including Compositae allergy were used to evaluate quality of life. As a result, we found that PUVA soaks has good effect in patients with psoriasis and hyperkeratotic hand eczema and local phototherapy for chronic hand dermatoses is a useful treatment option in selected cases.

show abstract

“…Despite the currently available therapies, the illness leads frequently to a chronic course [1,2]. It is well known that patient's quality of life is affected negatively by restricted function of the hands, severe psychological strain and also economical implications [3-5]. …”

Section: Introductionmentioning

confidence: 99%

“…The prevalence of patients with hand eczema is estimated at 7% to 12% in the general population [5,6]. However, the fraction of severe chronic hand eczema (CHE) among hand eczema patients is assumed to be 5-7%, whereas 2-4% are estimated to be refractory to topical steroids[7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective

Blank

Blank²,

Szucs

2010

BMC Dermatol

View full text Add to dashboard Cite

BackgroundThe impact on patients suffering from chronic hand eczema (CHE) is enormous, as no licensed systemic treatment option with proven efficacy for CHE is available. Alitretinoin is a novel agent which showed high clinical efficacy in patients with severe, refractory CHE. We assessed the cost-effectiveness of alitretinoin for CHE patient treatment from a Swiss third party payer perspective. A further objective of this study was to determine the burden of disease in Switzerland.MethodsA long-term Markov cohort simulation model was used to estimate direct medical costs (€) and clinical effectiveness (quality adjusted life years, QALYs) of treating severe CHE patients with alitretinoin. Comparison was against the standard treatment of supportive care (optimised emollient therapy). Information on response rates were derived from a randomized controlled clinical trial. Costs were considered from the perspective of the Swiss health system. Swiss epidemiological data was derived from official Swiss Statistic institutions.ResultsAnnual costs of alitretinoin treatment accounted for €2'212. After a time horizon of 22.4 years, average remaining long-term costs accounted for €42'208 or €38'795 in the alitretinoin and the standard treatment arm, respectively. Compared with the standard therapy, the addition of alitretinoin yielded an average gain of 0.230 QALYs at the end of the simulation. Accordingly, the incremental cost-effectiveness ratio resulted in €14'816/QALY gained. These results were robust to changes in key model assumptions.ConclusionThe therapy for CHE patients is currently insufficient. In our long-term model we identified the treatment with alitretinoin as a cost-effective alternative for the therapy of CHE patients in Switzerland.

show abstract

Chronic hand eczema

Cited by 11 publications

References 57 publications

Chronic Hand Eczema: Perception and Knowledge in Non-affected Individuals from General and Dermatological Practice

Chronic Hand Eczema: Perception and Knowledge in Non-affected Individuals from General and Dermatological Practice

Psoralen plus ultraviolet A (PUVA) soaks and UVB TL01 treatment for chronic hand dermatoses

Cost-effectiveness of oral alitretinoin in patients with severe chronic hand eczema - a long-term analysis from a Swiss perspective

Contact Info

Product

Resources

About